Ewing's sarcoma in children: Twenty‐five years of experience at the institute portuagěs de oncologia de francisco gentil (I.P.O.F.G.)

Abstract

Fifty children with Ewing's sarcoma were consecutively treated from 1962 to 1987 and retrospectively analyzed at the I.P.O.F.G. of Lisbon. At first diagnosis, 10 cases had distant metastases. The remaining 40 patients had clinically localized disease, and different protocols were followed over the years. The best results were obtained with chemotherapy and radiotherapy with or without surgery; and for these children the two-year survival rate was 42.8% vs. 8.3% for the group of patients submitted to local treatment alone. Besides the treatment modality, other factors influenced the prognosis, such as inflammatory signs, sex, tumor volume, and tumor site as well as evidence of distant metastases.

(iii) Musculoskeletal malignancy – non-surgical management

“…21 Since the 1970s aggressive chemotherapy has increased survival rates to 55e65% for local disease and up to 35% in primary metastatic disease. Treatment a patient receives depends on the site of the primary and the presence and distribution of any metastatic disease.…”

SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression

“…Before the era of combination chemotherapy, the prognosis of ES patients was poor, with more than 90% of patients dying from secondary metastases [9]. The current standard of care for ES consists mainly of chemotherapy with 5 drugs (vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide) and associated with local surgery or radiotherapy when surgery is difficult [10].…”

(v) The non-surgical management of musculoskeletal malignancy

“…Without systemic treatment more than 90% of patients die from secondary metastases. 17 Since the 1970's aggressive chemotherapy has increased survival rates to 55e65% for local disease and up to 35% in primary metastatic disease. The actual treatment a patient receives depends on the site of the primary and the presence and distribution of any metastatic disease.…”